Single institution experience with high‐dose cyclophosphamide, continuous infusion vincristine, escalating doses of VP‐16‐213, and total body irradiation with unpurged bone marrow rescue in children with neuroblastoma
Authors:
- 1 January 1992
- journal article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 20 (1) , 64-67
Abstract
Seven consecutive autologous bone marrow transplants were performed in children with neuroblastoma with very good partial remission (VGPR). A combination of cyclophosphamide, escalating doses of VP‐16‐213, continuous infusion vincristine, and total body irradiation followed by infusion with unpurged bone marrow was used. The dose‐limiting toxicity in this regimen was mucositis which occurred when the total dose of VP‐16‐213 was 2,400 mg/m2. The response rate to this regimen was 4/7 (‐CR 48+, 21+, 21+, 35+ mo) 3/7 had a CR/PR post transplant with progressive disease between 1 and 4 months later (mean 2.6 mo). We conclude that this regimen is well tolerated when the maximum dose of VP‐16‐213 does not exceed 1,800 mg/m2. Further evaluation will be necessary with this regimen to determine its therapeutic value in a larger number of patients with neuroblastoma.Keywords
This publication has 14 references indexed in Scilit:
- Allogeneic Bone Marrow Transplantation after Hyperfractionated Total-Body Irradiation and Cyclophosphamide in Children with Acute LeukemiaNew England Journal of Medicine, 1987
- Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1987
- Acute Graft-vs-Host DiseaseArchives of Dermatology, 1987
- Overview of the clinical relevance of autologous bone marrow transplantationClinics in Haematology, 1986
- High dose melphalan and autologous bone marrow transplantation for solid tumours of childhoodEuropean Paediatric Haematology and Oncology, 1984
- Autologous bone marrow transplantation contributes to haemopoietic recovery in children with solid tumours treated with high dose melphalanBritish Journal of Haematology, 1984
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984
- High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.Journal of Clinical Oncology, 1983
- Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer.Journal of Clinical Oncology, 1983
- Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level)The Journal of Pediatrics, 1972